Applied DNA Sciences (NASDAQ:APDN) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a research report issued on Sunday. The firm set a “hold” rating on the technology company’s stock.

Separately, HC Wainwright dropped their target price on Applied DNA Sciences from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Friday, February 9th.

Applied DNA Sciences Price Performance

Shares of Applied DNA Sciences stock opened at $0.34 on Friday. The firm has a market cap of $5.83 million, a price-to-earnings ratio of -0.64 and a beta of 0.07. The stock’s 50-day moving average is $0.49 and its 200-day moving average is $0.67. Applied DNA Sciences has a one year low of $0.31 and a one year high of $1.86.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings results on Thursday, February 8th. The technology company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.22. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $0.70 million. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. On average, equities analysts expect that Applied DNA Sciences will post -0.63 EPS for the current year.

Institutional Trading of Applied DNA Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. AMH Equity Ltd grew its position in shares of Applied DNA Sciences by 76.3% in the third quarter. AMH Equity Ltd now owns 587,232 shares of the technology company’s stock valued at $711,000 after purchasing an additional 254,232 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in Applied DNA Sciences during the fourth quarter worth approximately $61,000. Geode Capital Management LLC grew its position in Applied DNA Sciences by 28.8% during the fourth quarter. Geode Capital Management LLC now owns 129,355 shares of the technology company’s stock worth $214,000 after buying an additional 28,897 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Applied DNA Sciences during the third quarter worth approximately $146,000. Finally, Dimensional Fund Advisors LP grew its position in Applied DNA Sciences by 53.0% during the first quarter. Dimensional Fund Advisors LP now owns 65,916 shares of the technology company’s stock worth $141,000 after buying an additional 22,843 shares in the last quarter. Institutional investors own 22.22% of the company’s stock.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.